EWA
HRTX icon

EverSource Wealth Advisors’s Heron Therapeutics HRTX Stock Holding History

EverSource Wealth Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$420 Buy
984
+144
+17% +$115 ﹤0.01% 4161
2026
Q1 		$672 Buy
840
+199
+31% +$231 ﹤0.01% 3980
2025
Q4 		$833 Sell
641
-1,104
-63% -$1.36K ﹤0.01% 3757
2025
Q3 		$2.2K Buy
1,745
+1,550
+795% +$2.46K ﹤0.01% 3485
2025
Q2 		$404 Buy
195
+78
+67% +$159 ﹤0.01% 3950
2025
Q1 		$257 Buy
117
+84
+255% +$163 ﹤0.01% 3641
2024
Q4 		$50 Buy
+33
New +$53 ﹤0.01% 3637

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

EverSource Wealth Advisors's HRTX Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Heron Therapeutics (HRTX) stake by 17% in Q2 2026, buying an estimated $115 and bringing the position to 984 shares worth $420. The position accounts for ﹤0.01% of the portfolio, ranked #4161.

EverSource Wealth Advisors first reported a position in HRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.2K in Q3 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • EverSource Wealth Advisors held 984 shares of Heron Therapeutics worth $420 as of Q2 2026.
  • EverSource Wealth Advisors bought 144 Heron Therapeutics shares in Q2 2026, an estimated $115.
  • Heron Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4161 holding.
  • EverSource Wealth Advisors first reported a position in Heron Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • EverSource Wealth Advisors's Heron Therapeutics position peaked at $2.2K in Q3 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.